Last edition
News about "BioMarin Pharmaceutical "
BioMarin Reports Positive Phase 3 VOXZOGO Results in Hypochondroplasia
BioMarin reports positive phase 3 VOXZOGO results in children with hypochondroplasia, showing significant improvements in growth measures and supporting Food and Drug Administration (FDA) supplemental New Drug Application (sNDA).
BioMarin Pharmaceutical | 11/09/2026 | By News Bureau | 120
BioMarin, n-Lorem Partner to Develop First Investigational Therapy for ReNU Syndrome
BioMarin and the n-Lorem Foundation have partnered to develop an investigational antisense oligonucleotide therapy targeting the most common genetic variant associated with ReNU syndrome, a rare neurodevelopmental disorder with no approved treatments.
BioMarin Pharmaceutical | 28/07/2026 | By News Bureau | 122
US FDA Accepts BioMarin's sNDA for VOXZOGO in Achondroplasia
The US Food and Drug Administration (FDA) has accepted BioMarin's sNDA for VOXZOGO in achondroplasia, supported by long-term safety and efficacy data, including adult height, body proportionality, and arm span outcomes.
BioMarin Pharmaceutical | 14/07/2026 | By News Bureau | 129
BioMarin Strengthens its Leadership with New Appointments
At BioMarin, he will assume responsibility for the company's R&D organization, including discovery research, preclinical, translational and clinical programs, as well as global regulatory and medical affairs.
BioMarin Pharmaceutical | 22/08/2024 | By Aishwarya | 889
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy